Glucostop

Glucostop is an oral medication that contains Metformin Hydrochloride, a biguanide used for managing blood glucose levels. It is marketed in the European Union as a prescription‑only product, with strength not specified. Glucostop belongs to the antidiabetic therapeutic class and works by reducing hepatic glucose production while improving peripheral insulin sensitivity. It is intended for adult patients with type 2 diabetes mellitus and should be taken under medical supervision.

Glucostop is indicated for the treatment of type 2 diabetes mellitus as part of a comprehensive diabetes management plan.

- As monotherapy in patients who do not achieve glycemic control with diet and exercise alone. - In combination with other oral antidiabetic agents such as sulfonylureas, DPP‑4 inhibitors, or SGLT2 inhibitors. - As an adjunct to insulin therapy when additional glucose lowering is needed. - For patients with overweight or obesity to aid modest weight stabilization. - To improve insulin sensitivity in peripheral tissues.

The safety profile of Glucostop reflects the typical adverse events associated with metformin therapy.

Common: - Gastrointestinal upset such as nausea, abdominal discomfort, or diarrhea. - Metallic taste in the mouth. - Mild loss of appetite. - Headache.

Serious: - Lactic acidosis, a rare but potentially life‑threatening condition. - Severe hypoglycemia when combined with insulin or insulin secretagogues. - Significant elevation of liver enzymes. - Persistent vomiting leading to dehydration.

Healthcare providers should evaluate several precautionary factors before prescribing Glucostop to ensure safe use.

- Assess renal function; avoid use in patients with eGFR below 30 mL/min/1.73 m². - Review hepatic status, as liver disease may increase risk of lactic acidosis. - Monitor for signs of vitamin B12 deficiency with long‑term therapy. - Use caution in elderly patients due to higher incidence of gastrointestinal side effects. - Discontinue before any radiographic procedures that use iodinated contrast agents. - Consider dose adjustment during acute illness or dehydration.

Glucostop can interact with other medicines, affecting its efficacy or safety.

Avoid: - Iodinated contrast agents used for imaging studies; they may precipitate renal impairment. - Alcoholic beverages in excess, which can increase risk of lactic acidosis.

Use with caution: - Other antidiabetic drugs that cause hypoglycemia, such as sulfonylureas or insulin. - Cimetidine, which may increase metformin plasma concentrations. - Certain diuretics that affect renal clearance. - Medications that may interfere with vitamin B12 absorption, like proton pump inhibitors.